APC anti-human CD3 Antibody

Product Details

Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections^4,6,7 and formalin-fixed paraffin-embedded sections¹¹, immunoprecipitation¹, activation of T cells^2,3,5, Western blotting⁹, and spatial biology (IBEX)^16,17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300413, 300414, and 300432). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300437, 300438, 300465, 300466, 300473, 300474) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

1. Salmeron A, et al. 1991. J. Immunol. 147:3047. (IP)
2. Graves J, et al. 1991. J. Immunol. 146:2102. (Activ)
3. Lafont V, et al. 2000. J. Biol. Chem. 275:19282. (Activ)
4. Ryschich E, et al. 2003. Tissue Antigens 62:48. (IHC)
5. Thompson AG, et al. 2004. J. Immunol. 173:1671. (Activ)
6. Sakkas LI, et al. 1998. Clin. Diagn. Lab. Immun. 5:430. (IHC)
7. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
8. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
9. Van Dongen JJM, et al. 1988. Blood 71:603. (WB)
10. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
11. Pollard, K. et al. 1987. J. Histochem. Cytochem. 35:1329. (IHC)
12. Luckashenak N, et al. 2013. J. Immunol. 190:27. PubMed
13. Laurent AJ, et al. 2014. PLoS One. 9:103683. PubMed
14. Li J, et al. 2015. Cancer Res. 75:508. PubMed
15. Stoeckius M, et al. 2017. Nat. Methods. 14:865-868. (PG)
16. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Lichtenegger FS, et al. 2018. Front Immunol. 9:385. PubMed
2. Toepfner N et al. 2018. eLife. 7 pii: e29213. PubMed
3. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
4. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
5. Meraviglia S, et al. 2017. Oncoimmunology. 6:e1347742. PubMed
6. Fujii S, et al. 2019. Stem Cells Dev. 28:28. PubMed
7. Tognarelli S, et al. 2018. Front Immunol. 9:2743. PubMed
8. Anderson NR, et al. 2019. Cell Adh Migr. 13:163. PubMed
9. Mayassi T, et al. 2019. Cell. 176:967. PubMed
10. Levring TB, et al. 2019. Sci Rep. 9:16725. PubMed
11. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
12. Good Z, et al. 2019. Nat Biotechnol. 37:259. PubMed
13. Giron LB, et al. 2020. EBioMedicine. 73.94791667. PubMed
14. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
15. Martin–Fernandez M, et al. 2020. Cell Reports. 31(6):107633. PubMed
16. Katsuyama E, et al. 2020. Cell Reports. 30(1):112-123.e4.. PubMed
17. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
18. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
19. Zhong J, et al. 2018. Sci Adv. 4:eaas9864. PubMed
20. Kim JR, et al. 2005. BMC Immunol. 2005,6:3. PubMed
21. Siegers G, et al. 2011. PLoS One. 6:e16700. PubMed
22. Gutzeit C, et al. 2014. J Immunol. 192:5852. PubMed
23. Headland S, et al. 2014. Sci Rep. 4:5237. PubMed
24. Gerstner S, et al. 2016. J Leukoc Biol. 100(6):1297-1310. PubMed
25. Crawford MP, et al. 2020. Proc Natl Acad Sci U S A. 117:19408. PubMed
26. Huang GL, et al. 2020. PLoS One. 15:e0241421. PubMed
27. Barresi V, et al. 2020. J Clin Med. 9:00. PubMed
28. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
29. Constantinescu-Bercu A, et al. 2020. eLife. 9:00. PubMed
30. Lavaert M, et al. 2020. Frontiers in Immunology. 1.610416667. PubMed
31. Le J, et al. 2020. Immunity. 52(6):1105-1118.e9. PubMed
32. Zhang B, et al. 2020. Cell Chemical Biology. 28(1):60-69.e7. PubMed
33. Wang C, et al. 2021. Cell Stem Cell. . PubMed
34. Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed
35. Hannon E, et al. 2021. PLoS Genet. e1009443:17. PubMed
36. Helmink BA, et al. 2020. Nature. 577:549. PubMed
37. Morton B, et al. 2021. Nat Commun. 12:3554. PubMed
38. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
39. Lu P, et al. 2021. Blood Cancer J. 11:39. PubMed
40. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
41. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
42. Jacoby E, et al. 2021. NPJ Regen Med. 6:58. PubMed
43. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
44. Jing L, et al. 2020. Cancer Immunol Res. 8:648. PubMed
45. Singh KS, et al. 2021. Nature. 589:597. PubMed
46. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
47. Hu H, et al. 2022. Exp Ther Med. 24:487. PubMed
48. Lo Presti E, et al. 2020. J Leukoc Biol. 108:749. PubMed
49. Sun L, et al. 2020. J Diabetes Res. 2020:2583257. PubMed
50. Ogishi M, et al. 2021. Nat Med. 27:1646. PubMed
51. Ling X, et al. 2022. STAR Protoc. 3:101321. PubMed
52. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
53. Paris O, et al. 2022. Front Immunol. 13:975910. PubMed
54. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
55. Wheeler MM, et al. 2022. Nat Commun. 13:7592. PubMed
56. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
57. Yen M, et al. 2022. Cell. 185:1414. PubMed
58. Zhang Y, et al. 2023. Heliyon. 9:e14823. PubMed
59. Crawford MP, et al. 2023. PLoS One. 18:e0285166. PubMed
60. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed

RRID

AB_314065 (BioLegend Cat. No. 300411)
AB_314066 (BioLegend Cat. No. 300412)
AB_2564151 (BioLegend Cat. No. 300458)
AB_2562045 (BioLegend Cat. No. 300439)

Antigen Details

Structure

Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD

Distribution

Mature T and NK T cells, thymocyte differentiation

Function

Antigen recognition, signal transduction, T cell activation

Ligand/Receptor

Peptide antigen bound to MHC

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology, Innate Immunity

Molecular Family

CD Molecules, TCRs

Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID

916 View all products for this Gene ID

UniProt

View information about CD3 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis